Shares of Replimune Group Inc. (REPL) surged 5.71% in pre-market trading on Friday, following the company's filing for a mixed shelf offering of up to $250 million. This significant move comes as the biotechnology firm positions itself for potential future growth and capital raising opportunities.

The mixed shelf filing, reported in an SEC filing early Friday, allows Replimune to issue various types of securities, including common stock, preferred stock, debt securities, warrants, or a combination thereof, up to a total value of $250 million. This strategic financial move provides the company with flexibility to raise capital as needed over time, which investors seem to view favorably.

While the exact use of the potential proceeds wasn't immediately specified, such filings are often seen as a proactive step by companies to ensure ready access to capital for various corporate purposes, including research and development, potential acquisitions, or general working capital. The positive pre-market reaction suggests that investors are optimistic about Replimune's future plans and the potential use of any raised funds.